8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 17, 2026·SEC
Medifast, Inc.(MED)Earnings, Financials & Key Ratios
MED•NYSE
$13.02
$144M mkt cap·Price updated May 6, 2026
AboutMedifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.Show more
- Revenue$386M-36.0%
- EBITDA-$4M-123.8%
- Net Income-$19M-993.0%
- EPS (Diluted)-1.70-994.7%
- Gross Margin71.33%-3.3%
- EBITDA Margin-0.96%-137.2%
- Operating Margin-3.68%-871.2%
- Net Margin-4.84%-1494.4%
- ROE-9.13%-998.5%
- ROIC-8.15%-598.9%
- Debt/Equity0.08+9.9%
MED Key Insights
Medifast, Inc. (MED) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Good 3Y average ROE of 15.9%
- ✓Trading at only 0.7x book value
- ✓Efficient asset utilization: 1.5x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Sales declining 16.2% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MED Price & Volume
Medifast, Inc. (MED) stock price & volume — 10-year historical chart
Loading chart...
MED Growth Metrics
Medifast, Inc. (MED) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.53%
5 Years-16.22%
3 Years-37.74%
TTM-36.31%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-186.19%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-181.54%
Return on Capital
10 Years56.77%
5 Years52.12%
3 Years19.7%
Last Year-6.55%
MED Recent Earnings
Medifast, Inc. (MED) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 4, 2026EPS
$0.19
Est $0.55
+65.5%
Revenue
$76M
Est $69M
+9.9%
Q1 2026
Feb 17, 2026EPS
$0.55
Est $0.76
+27.6%
Revenue
$75M
Est $71M
+5.2%
Q4 2025
Nov 3, 2025EPS
$0.21
Est $0.01
-2000.0%
Revenue
$89M
Est $71M
+25.2%
Q3 2025
Aug 4, 2025EPS
$0.04
Est $0.30
+113.3%
Revenue
$106M
Est $94M
+12.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.19vs $0.55+65.5% | $76Mvs $69M+9.9% |
| Q1 2026 | Feb 17, 2026 | $0.55vs $0.76+27.6% | $75Mvs $71M+5.2% |
| Q4 2025 | Nov 3, 2025 | $0.21vs $0.01-2000.0% | $89Mvs $71M+25.2% |
| Q3 2025 | Aug 4, 2025 | $0.04vs $0.30+113.3% | $106Mvs $94M+12.5% |
Based on last 12 quarters of dataView full earnings history →
MED Peer Comparison
Medifast, Inc. (MED) competitors in Health, Fitness and Wellness Services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HIMS | 6.8B | 26.33 | 51.63 | 59% | 5.47% | 23.73% | 1.09% | 2.07 |
 NUS | 353.31M | 7.33 | 2.31 | -14.26% | 7.02% | 13.7% | 13.02% | 0.35 |
 USNA | 355.48M | 19.26 | 33.21 | 8.28% | 1.16% | 1.84% | 2.4% | 0.02 |
 RVLV | 1.67B | 23.44 | 27.26 | 8.48% | 5.05% | 12.84% | 2.87% | 0.06 |
 WW | 118.96M | 11.90 | 0.11 | -9.58% | 148.6% | 332% | 1.47 | |
 HLF | 1.68B | 16.26 | 7.39 | 0.89% | 4.53% | 15.06% | ||
 PLNT | 5.34B | 64.31 | 32.16 | 10.3% | 15.97% | 3.54% | ||
 XPOF | 243.27M | 6.52 | -4.44 | -1.71% | -11.08% | 10.17% |
Compare MED vs Peers
Medifast, Inc. (MED) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MED Income Statement
Medifast, Inc. (MED) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 301.56M | 501M | 713.67M | 934.84M | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M | 346.1M |
| Revenue Growth % | 9.85% | 66.14% | 42.45% | 30.99% | 63.25% | 4.75% | -32.94% | -43.8% | -35.96% | -36.31% |
| Cost of Goods Sold | 73.75M | 121.1M | 176.81M | 237.03M | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M | 103.41M |
| COGS % of Revenue | 24.46% | 24.17% | 24.78% | 25.35% | 26.11% | 28.66% | 27.63% | 26.2% | 28.67% | - |
| Gross Profit | 227.81M▲ 0% | 379.9M▲ 66.8% | 536.86M▲ 41.3% | 697.82M▲ 30.0% | 1.13B▲ 61.6% | 1.14B▲ 1.1% | 775.85M▼ 32.0% | 444.62M▼ 42.7% | 275.19M▼ 38.1% | 242.7M▲ 0% |
| Gross Margin % | 75.54% | 75.83% | 75.22% | 74.65% | 73.89% | 71.34% | 72.37% | 73.8% | 71.33% | 70.12% |
| Gross Profit Growth % | 10.77% | 66.76% | 41.32% | 29.98% | 61.59% | 1.14% | -31.97% | -42.69% | -38.11% | - |
| Operating Expenses | 188.18M | 310.84M | 445.82M | 563.66M | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M | 258.94M |
| OpEx % of Revenue | 62.4% | 62.04% | 62.47% | 60.29% | 59.72% | 59.78% | 60.58% | 73.32% | 75.02% | - |
| Selling, General & Admin | 188.18M | 310.84M | 445.82M | 563.66M | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M | 258.94M |
| SG&A % of Revenue | 62.4% | 62.04% | 62.47% | 60.29% | 59.72% | 59.78% | 60.58% | 73.32% | 75.02% | - |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 39.63M▲ 0% | 69.06M▲ 74.3% | 91.04M▲ 31.8% | 134.16M▲ 47.4% | 216.24M▲ 61.2% | 184.81M▼ 14.5% | 126.4M▼ 31.6% | 2.88M▼ 97.7% | -14.21M▼ 593.8% | -16.25M▲ 0% |
| Operating Margin % | 13.14% | 13.78% | 12.76% | 14.35% | 14.17% | 11.56% | 11.79% | 0.48% | -3.68% | -4.69% |
| Operating Income Growth % | 47.56% | 74.26% | 31.82% | 47.36% | 61.18% | -14.54% | -31.6% | -97.72% | -593.85% | - |
| EBITDA | 43.84M | 73.5M | 95.66M | 138.47M | 223.05M | 195.79M | 139.51M | 15.59M | -3.71M | -5.28M |
| EBITDA Margin % | 14.54% | 14.67% | 13.4% | 14.81% | 14.62% | 12.25% | 13.01% | 2.59% | -0.96% | -1.53% |
| EBITDA Growth % | 35.88% | 67.65% | 30.16% | 44.75% | 61.08% | -12.22% | -28.74% | -88.83% | -123.82% | -182.51% |
| D&A (Non-Cash Add-back) | 4.21M | 4.43M | 4.62M | 4.32M | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M | 10.96M |
| EBIT | 39.63M | 69.06M | 91.04M | 134.16M | 216.24M | 184.76M | 126.4M | 2.88M | -14.21M | -11.53M |
| Net Interest Income | 558K | 1.31M | 1.29M | 246K | 0 | -701K | 2.49M | 4.8M | 5.52M | 4.21M |
| Interest Income | 558K | 1.31M | 1.29M | 246K | 0 | 0 | 2.49M | 4.8M | 5.52M | 5.59M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 701K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 694K | 1.49M | 1.32M | 106K | -112K | -747K | 2.4M | 909K | 8.57M | 8.14M |
| Pretax Income | 40.33M▲ 0% | 70.55M▲ 74.9% | 92.36M▲ 30.9% | 134.26M▲ 45.4% | 216.13M▲ 61.0% | 184.06M▼ 14.8% | 128.8M▼ 30.0% | 3.79M▼ 97.1% | -5.64M▼ 248.9% | -8.11M▲ 0% |
| Pretax Margin % | 13.37% | 14.08% | 12.94% | 14.36% | 14.16% | 11.51% | 12.01% | 0.63% | -1.46% | -2.34% |
| Income Tax | 12.61M | 14.76M | 14.45M | 31.41M | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M | 11.92M |
| Effective Tax Rate % | 31.26% | 20.92% | 15.64% | 23.39% | 24.11% | 22% | 22.81% | 44.78% | -231.12% | -147.03% |
| Net Income | 27.72M▲ 0% | 55.79M▲ 101.3% | 77.92M▲ 39.7% | 102.86M▲ 32.0% | 164.03M▲ 59.5% | 143.57M▼ 12.5% | 99.42M▼ 30.8% | 2.09M▼ 97.9% | -18.67M▼ 993.0% | -20.02M▲ 0% |
| Net Margin % | 9.19% | 11.14% | 10.92% | 11% | 10.75% | 8.98% | 9.27% | 0.35% | -4.84% | -5.79% |
| Net Income Growth % | 55.43% | 101.25% | 39.66% | 32.01% | 59.47% | -12.48% | -30.75% | -97.9% | -992.97% | -186.19% |
| Net Income (Continuing) | 27.72M | 55.79M | 77.92M | 102.86M | 164.03M | 143.57M | 99.42M | 2.09M | -18.67M | -20.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 2.29▲ 0% | 4.62▲ 101.7% | 6.43▲ 39.2% | 8.68▲ 35.0% | 13.89▲ 60.0% | 12.73▼ 8.4% | 9.10▼ 28.5% | 0.19▼ 97.9% | -1.70▼ 994.7% | -1.82▲ 0% |
| EPS Growth % | 53.69% | 101.75% | 39.18% | 34.99% | 60.02% | -8.35% | -28.52% | -97.91% | -994.74% | -181.54% |
| EPS (Basic) | 2.32 | 4.67 | 6.62 | 8.74 | 14.01 | 12.82 | 9.10 | 0.19 | -1.70 | - |
| Diluted Shares Outstanding | 12.09M | 12.08M | 12.12M | 11.85M | 11.81M | 11.28M | 10.92M | 10.96M | 10.98M | 11.01M |
| Basic Shares Outstanding | 11.92M | 11.95M | 11.77M | 11.77M | 11.71M | 11.2M | 10.88M | 10.93M | 10.98M | 11.01M |
| Dividend Payout Ratio | 55.52% | 41.51% | 45.43% | 51.71% | 38.93% | 49.89% | 73.45% | 34.19% | - | - |
MED Balance Sheet
Medifast, Inc. (MED) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 125.2M | 145.52M | 154.15M | 234.31M | 306.87M | 222.78M | 224.03M | 214.4M | 201.68M | 202.63M |
| Cash & Short-Term Investments | 98.83M | 101.03M | 92.68M | 174.47M | 109.54M | 87.69M | 150.04M | 162.34M | 167.27M | 71.53M |
| Cash Only | 75.08M | 81.36M | 76.97M | 163.72M | 104.18M | 87.69M | 94.44M | 90.93M | 89.3M | 71.53M |
| Short-Term Investments | 23.76M | 19.67M | 15.7M | 10.75M | 5.36M | 0 | 55.6M | 71.42M | 77.97M | 0 |
| Accounts Receivable | 576K | 1.01M | 1.44M | 584K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 0.7 | 0.74 | 0.73 | 0.23 | - | - | - | - | - | - |
| Inventory | 19.33M | 38.89M | 48.77M | 53.39M | 180.04M | 118.86M | 54.59M | 42.42M | 20.23M | 21.4M |
| Days Inventory Outstanding | 95.66 | 117.21 | 100.68 | 82.22 | 164.91 | 94.69 | 67.27 | 98.1 | 66.76 | 83.87 |
| Other Current Assets | 0 | 0 | 0 | -584K | 16.33M | 16.24M | 0 | 0 | 9.07M | 109.7M |
| Total Non-Current Assets | 20.73M | 23.91M | 40.5M | 41.77M | 91.46M | 93.43M | 85.88M | 69.81M | 55.33M | 49.42M |
| Property, Plant & Equipment | 18.61M | 19.75M | 38.84M | 38.14M | 80.59M | 75.64M | 67.11M | 48.68M | 38.46M | 42.56M |
| Fixed Asset Turnover | 16.20x | 25.37x | 18.37x | 24.51x | 18.94x | 21.13x | 15.97x | 12.38x | 10.03x | 8.35x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.12M | 1.18M | 353K | 2.94M | 6.47M | 12.46M | 14.65M | 9.67M | 7.83M | 29.68M |
| Total Assets | 145.93M▲ 0% | 169.43M▲ 16.1% | 194.65M▲ 14.9% | 276.08M▲ 41.8% | 398.33M▲ 44.3% | 316.21M▼ 20.6% | 309.91M▼ 2.0% | 284.21M▼ 8.3% | 257.01M▼ 9.6% | 252.05M▲ 0% |
| Asset Turnover | 2.07x | 2.96x | 3.67x | 3.39x | 3.83x | 5.06x | 3.46x | 2.12x | 1.50x | 1.32x |
| Asset Growth % | 20.39% | 16.1% | 14.89% | 41.83% | 44.28% | -20.61% | -1.99% | -8.29% | -9.57% | -35.71% |
| Total Current Liabilities | 37.14M | 60.32M | 79.39M | 111.35M | 169.83M | 140.89M | 92.3M | 64.16M | 42.96M | 42.18M |
| Accounts Payable | 13.8M | 19.02M | 22.61M | 36.09M | 70.89M | 53.12M | 39.19M | 23.05M | 15.07M | 0 |
| Days Payables Outstanding | 68.28 | 57.32 | 46.67 | 55.58 | 64.94 | 42.32 | 48.3 | 53.3 | 49.72 | 105.77 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.6M | 3.92M |
| Deferred Revenue (Current) | 0 | 0 | 4.33M | 7.61M | 8.05M | 7.36M | 574K | 316K | 384K | 0 |
| Other Current Liabilities | 0 | 19.76M | 0 | 0 | 0 | 0 | 0 | 32.77M | 13.63M | 38.26M |
| Current Ratio | 3.37x | 2.41x | 1.94x | 2.10x | 1.81x | 1.58x | 2.43x | 3.34x | 4.69x | 4.69x |
| Quick Ratio | 2.85x | 1.77x | 1.33x | 1.62x | 0.75x | 0.74x | 1.84x | 2.68x | 4.22x | 4.22x |
| Cash Conversion Cycle | 28.07 | 60.63 | 54.74 | 26.87 | - | - | - | - | - | -21.91 |
| Total Non-Current Liabilities | 208K | 1.97M | 10.43M | 7.49M | 26.02M | 20.27M | 16.13M | 9.94M | 15.13M | 12.18M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.09M | 12.18M |
| Capital Lease Obligations | 0 | 0 | 10.43M | 7.49M | 26.02M | 20.27M | 16.13M | 9.94M | 6.09M | 20.02M |
| Deferred Tax Liabilities | 208K | 1.97M | 0 | 0 | 0 | 0 | 0 | 0 | 9.04M | 9.04M |
| Other Non-Current Liabilities | 0 | -1.97M | 0 | 0 | 0 | 0 | 0 | 0 | -6.09M | -6.09M |
| Total Liabilities | 37.35M | 60.32M | 89.82M | 118.84M | 195.85M | 161.17M | 108.43M | 74.1M | 58.09M | 54.37M |
| Total Debt | 0 | 0 | 13.6M | 11.16M | 32.54M | 26.05M | 22.01M | 16.13M | 16.79M | 16.1M |
| Net Debt | -75.08M | -81.36M | -63.37M | -152.56M | -71.64M | -61.64M | -72.43M | -74.8M | -72.52M | -55.43M |
| Debt / Equity | - | - | 0.13x | 0.07x | 0.16x | 0.17x | 0.11x | 0.08x | 0.08x | 0.08x |
| Debt / EBITDA | - | - | 0.14x | 0.08x | 0.15x | 0.13x | 0.16x | 1.03x | - | -3.05x |
| Net Debt / EBITDA | -1.71x | -1.11x | -0.66x | -1.10x | -0.32x | -0.31x | -0.52x | -4.80x | - | 10.49x |
| Interest Coverage | - | - | - | - | - | 263.57x | - | - | - | - |
| Total Equity | 108.58M▲ 0% | 109.11M▲ 0.5% | 104.83M▼ 3.9% | 157.25M▲ 50.0% | 202.47M▲ 28.8% | 155.04M▼ 23.4% | 201.48M▲ 30.0% | 210.11M▲ 4.3% | 198.92M▼ 5.3% | 197.68M▲ 0% |
| Equity Growth % | 13.09% | 0.48% | -3.92% | 50% | 28.76% | -23.43% | 29.95% | 4.28% | -5.33% | -2.84% |
| Book Value per Share | 8.98 | 9.03 | 8.65 | 13.27 | 17.14 | 13.75 | 18.45 | 19.17 | 18.11 | 17.96 |
| Total Shareholders' Equity | 108.58M | 109.11M | 104.83M | 157.25M | 202.47M | 155.04M | 201.48M | 210.11M | 198.92M | 197.68M |
| Common Stock | 12K | 12K | 12K | 12K | 12K | 11K | 11K | 11K | 11K | 0 |
| Retained Earnings | 103.76M | 131.34M | 168.79M | 154.35M | 190.33M | 139.85M | 174.65M | 176.78M | 158.27M | 156.15M |
| Treasury Stock | 0 | -30.88M | -63.99M | -5M | 0 | -6.4M | 0 | 0 | 0 | 0 |
| Accumulated OCI | -160K | -173K | 25K | 41K | 111K | 24K | 248K | 180K | 234K | 33K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MED Cash Flow Statement
Medifast, Inc. (MED) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 43.24M | 60.82M | 84.26M | 145.2M | 94.55M | 194.57M | 147.66M | 24.48M | 6.86M | 6.86M |
| Operating CF Margin % | 14.34% | 12.14% | 11.81% | 15.53% | 6.2% | 12.17% | 13.77% | 4.06% | 1.78% | - |
| Operating CF Growth % | 70.56% | 40.66% | 38.55% | 72.32% | -34.88% | 105.8% | -24.11% | -83.42% | -71.96% | -191.38% |
| Net Income | 27.72M | 55.79M | 77.92M | 102.86M | 164.03M | 143.57M | 99.42M | 2.09M | -18.67M | -20.02M |
| Depreciation & Amortization | 4.21M | 4.43M | 4.62M | 4.32M | 6.81M | 10.98M | 13.11M | 17.4M | 14.24M | 14.45M |
| Stock-Based Compensation | 4.27M | 3.12M | 4.52M | 6.8M | 9.9M | 11.05M | 8.19M | 7.36M | 7.64M | 5.43M |
| Deferred Taxes | -623K | -2.69M | 1.6M | 601K | -3.71M | -924K | 1.21M | -7.4M | 11.46M | 11.44M |
| Other Non-Cash Items | 879K | 622K | 3.1M | 3.72M | 5.16M | 8.24M | 5.46M | 14.77M | 2M | 459K |
| Working Capital Changes | 6.78M | -467K | -7.49M | 26.9M | -87.65M | 21.65M | 20.28M | -9.74M | -9.8M | -8.04M |
| Change in Receivables | 815K | 122K | -4.06M | 297K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -1.02M | -18.66M | -9.88M | -4.62M | -126.65M | 61.19M | 64.27M | 12.17M | 22.19M | 17.96M |
| Change in Payables | 8.01M | 15.8M | 0 | 0 | 0 | -37.59M | -35.71M | -34.99M | -23.91M | -19.36M |
| Cash from Investing | -3.16M | -1.2M | -6.33M | -1.28M | -29.06M | -11.41M | -61.05M | -26.52M | -7.93M | -23.01M |
| Capital Expenditures | -3.24M | -4.94M | -10.06M | -5.89M | -34.21M | -16.68M | -6.48M | -7.45M | -5.61M | -5.19M |
| CapEx % of Revenue | 1.08% | 0.99% | 1.41% | 0.63% | 2.24% | 1.04% | 0.6% | 1.24% | 1.46% | - |
| Acquisitions | 81K | 196K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 81K | 196K | 0 | 0 | 0 | 0 | 0 | 95K | 3.31M | 3.66M |
| Cash from Financing | -17.36M | -53.33M | -82.32M | -57.14M | -125.13M | -199.58M | -79.79M | -1.51M | -564K | -902K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | -2.54M | -30.71M | -47.21M | -5.55M | -62.09M | -127.96M | -6.96M | -836K | -369K | 0 |
| Dividends Paid | -15.39M | -23.16M | -35.4M | -53.19M | -63.86M | -71.62M | -73.02M | -715K | -195K | -88K |
| Share Repurchases | -2.54M | -30.71M | -47.21M | -5.55M | -62.09M | -127.96M | -6.96M | -836K | -369K | 370K |
| Other Financing | 568K | 547K | 278K | 1.6M | 811K | 0 | 188K | 36K | 0 | -814K |
| Net Change in Cash | 22.64M▲ 0% | 6.29M▼ 72.2% | -4.39M▼ 169.8% | 86.75M▲ 2076.1% | -59.54M▼ 168.6% | -16.49M▲ 72.3% | 6.75M▲ 140.9% | -3.51M▼ 152.0% | -1.63M▲ 53.7% | -20.19M▲ 0% |
| Free Cash Flow | 39.99M▲ 0% | 55.88M▲ 39.7% | 74.2M▲ 32.8% | 139.31M▲ 87.7% | 60.34M▼ 56.7% | 177.89M▲ 194.8% | 141.17M▼ 20.6% | 17.02M▼ 87.9% | 1.25M▼ 92.7% | -1.47M▲ 0% |
| FCF Margin % | 13.26% | 11.15% | 10.4% | 14.9% | 3.95% | 11.13% | 13.17% | 2.83% | 0.32% | -0.43% |
| FCF Growth % | 77.96% | 39.71% | 32.8% | 87.74% | -56.69% | 194.83% | -20.64% | -87.94% | -92.66% | -110.92% |
| FCF per Share | 3.31 | 4.63 | 6.12 | 11.76 | 5.11 | 15.78 | 12.93 | 1.55 | 0.11 | 0.11 |
| FCF Conversion (FCF/Net Income) | 1.56x | 1.09x | 1.08x | 1.41x | 0.58x | 1.36x | 1.49x | 11.71x | -0.37x | 0.07x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 13.62M | 14.61M | 17.31M | 24.64M | 56.76M | 37.21M | 34.26M | 0 | 0 | 7.1M |
MED Key Ratios
Medifast, Inc. (MED) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 27.1% | 51.26% | 72.84% | 78.5% | 91.2% | 80.31% | 55.77% | 1.02% | -9.13% | -9.68% |
| Return on Invested Capital (ROIC) | 76.35% | 169.14% | 197.34% | 436.12% | 239.35% | 123.62% | 85.23% | 1.63% | -8.15% | -8.15% |
| Gross Margin | 75.54% | 75.83% | 75.22% | 74.65% | 73.89% | 71.34% | 72.37% | 73.8% | 71.33% | 70.12% |
| Net Margin | 9.19% | 11.14% | 10.92% | 11% | 10.75% | 8.98% | 9.27% | 0.35% | -4.84% | -5.79% |
| Debt / Equity | - | - | 0.13x | 0.07x | 0.16x | 0.17x | 0.11x | 0.08x | 0.08x | 0.08x |
| Interest Coverage | - | - | - | - | - | 263.57x | - | - | - | - |
| FCF Conversion | 1.56x | 1.09x | 1.08x | 1.41x | 0.58x | 1.36x | 1.49x | 11.71x | -0.37x | 0.07x |
| Revenue Growth | 9.85% | 66.14% | 42.45% | 30.99% | 63.25% | 4.75% | -32.94% | -43.8% | -35.96% | -36.31% |
MED SEC Filings & Documents
Medifast, Inc. (MED) SEC filings — annual & quarterly reports (10-K, 10-Q)
MED Frequently Asked Questions
Medifast, Inc. (MED) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Medifast, Inc. (MED) reported $346.1M in revenue for fiscal year 2025. This represents a 1997% increase from $16.5M in 1996.
Medifast, Inc. (MED) saw revenue decline by 36.0% over the past year.
Medifast, Inc. (MED) reported a net loss of $20.0M for fiscal year 2025.
Dividend & Returns
Yes, Medifast, Inc. (MED) pays a dividend with a yield of 0.14%. This makes it attractive for income-focused investors.
Medifast, Inc. (MED) has a return on equity (ROE) of -9.1%. Negative ROE indicates the company is unprofitable.
Medifast, Inc. (MED) had negative free cash flow of $1.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More MED
Medifast, Inc. (MED) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates